Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPPA adjuvant capecitabine plus pembrolizumab in TNBC with residual disease
2023-505291-30-01Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine and pembrolizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Unicancer. Primary endpoint: 2-year invasive disease-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
capecitabinepembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-505291-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505291-30-01.